GLAXOSMITHKLINE

GlaxoSmithKline, LLC specializes in the end-to-end manufacturing and development of pharmaceutical and biological products, with deep expertise in clinical-scale production of influenza vaccines, adjuvanted antigens, and CGMP-compliant bulk drug substances. The contractor excels in fill/finish operations for pandemic-ready vaccine candidates, including the formulation and stabilization of MF59 and AS03 adjuvants, and conducts critical physical and chemical compatibility studies to support antigen-adjuvant combinations. Their technical capabilities span biopharmaceutical process development, aseptic manufacturing, and regulatory-aligned production of seasonal and pandemic influenza vaccines for adult and pediatric populations, with demonstrated proficiency in supporting public health emergency responses. The contractor maintains a consistent partnership with the Department of Health and Human Services and the Department of Justice, delivering mission-critical vaccine supply chains for federal correctional facilities and public health programs. For HHS, they provide seasonal and novel strain influenza vaccines under strict biosafety and cold chain protocols, while for the Department of Justice, they ensure secure, compliant delivery of vaccines to incarcerated populations. Their engagement with the Department of Veterans Affairs further underscores their role in sustaining veteran-specific immunization programs. Their primary industry focus lies in pharmaceutical preparation manufacturing (NAICS 325412) and biological product manufacturing (325414), positioning them as a trusted producer of immunobiologics for government health security initiatives. They also engage in biotechnology research and development (541714), particularly in adjuvant integration and antigen stability, reinforcing their niche in next-generation vaccine platforms. As a 2L entity headquartered in Durham, NC, GlaxoSmithKline, LLC operates as a large-scale manufacturer with established cGMP facilities and regulatory infrastructure. Though no specific government certifications are listed, their consistent award history reflects full compliance with federal quality and supply chain requirements for sensitive biological products. Their geographic presence and operational scale make them a key contributor to the U.S. government’s biodefense and public health preparedness ecosystem.